Search Results - "BOSL, G. J"

Testicular Germ-Cell Cancer by Bosl, George J, Motzer, Robert J

“…Approximately 95 percent of malignant tumors arising in the testis are germ-cell tumors, a term that indicates their origin in primordial germ cells. Germ-cell…”
Get full text

Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy by MAZUMDAR, M, BAJORIN, D. F, BACIK, J, HIGGINS, G, MOTZER, R. J, BOSL, G. J

“…The prognostic significance of the rate of decline of the serum tumor marker alpha-fetoprotein (AFP) and human chorionic gonadotrophin (HCG) during the first…”
Get full text

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design by Chou, T C, Motzer, R J, Tong, Y, Bosl, G J

“…Cisplatin-based induction chemotherapy may achieve a complete response (i.e., no sign of tumor following treatment) in 70%-80% of patients with germ cell…”
Get more information

Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer by MOTZER, R. J, SHEINFELD, J, MAZUMDAR, M, BAINS, M, MARIANI, T, BACIK, J, BAJORIN, D, BOSL, G. J

“…To evaluate the dose, toxicity, and efficacy of paclitaxel in combination with ifosfamide and cisplatin as salvage therapy for patients with relapsed…”
Get full text

High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity by Motzer, R J, Mazumdar, M, Bosl, G J, Bajorin, D F, Amsterdam, A, Vlamis, V

“…The efficacy and toxicity of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation (AuBMT) was investigated in a…”
Get more information

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors by Motzer, R J, Mazumdar, M, Bajorin, D F, Bosl, G J, Lyn, P, Vlamis, V

“…A treatment program that included high-dose carboplatin, etoposide, and cyclophosphamide (CEC) followed by autologous bone marrow transplantation (AuBMT) was…”
Get more information

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival by McCaffrey, J A, Mazumdar, M, Bajorin, D F, Bosl, G J, Vlamis, V, Motzer, R J

“…To evaluate the efficacy and toxicity of ifosfamide- and cisplatin-containing chemotherapy as first-line salvage treatment for patients with germ cell tumors…”
Get more information

Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors by Motzer, R J, Amsterdam, A, Prieto, V, Sheinfeld, J, Murty, V V, Mazumdar, M, Bosl, G J, Chaganti, R S, Reuter, V E

“…Teratoma with malignant transformation refers to a form of germ cell tumor in which a somatic teratomatous component becomes morphologically malignant and…”
Get more information

Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center by Puc, H S, Heelan, R, Mazumdar, M, Herr, H, Scheinfeld, J, Vlamis, V, Bajorin, D F, Bosl, G J, Mencel, P, Motzer, R J

“…Guidelines for management of postchemotherapy residual mass in patients with advanced seminoma remain controversial. We sought to characterize independent…”
Get more information

Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients by MOTZER, R. J, MAZUMDAR, M, BOSL, G. J, SHEINFELD, J, BAJORIN, D. F, MACAPINLAC, H. A, BAINS, M, REICH, L, FLOMBAUM, C, MARIANI, T, TONG, W. P

“…To evaluate the efficacy and toxicity of sequential, dose-intensified chemotherapy with paclitaxel/ifosfamide and carboplatin/etoposide administered plus…”
Get full text

Telomerase Activity in Germ Cell Cancers and Mature Teratomas by Albanell, Juan, Bosl, George J., Reuter, Victor E., Engelhardt, Monika, Franco, Sonia, Moore, Malcolm A. S., Dmitrovsky, Ethan

“…BACKGROUND: An inverse relationship has been reported between the presence of telomerase enzymatic activity and the induction of differentiation in human tumor…”
Get full text

Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation by HOULDSWORTH, J, HAN XIAO, MURTY, V. V. V. S, WEIYI CHEN, RAY, B, REUTER, V. E, BOSL, G. J, CHAGANTI, R. S. K

“…Male germ cell tumors (GCTs) are uniquely sensitive to cisplatin-based chemotherapy, with more than 90% of newly diagnosed cases cured. The underlying cause…”
Get full text

Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients by Mencel, P J, Motzer, R J, Mazumdar, M, Vlamis, V, Bajorin, D F, Bosl, G J

“…To investigate the efficacy of chemotherapy and to assess the relationship between selected pretreatment characteristics and survival in patients with advanced…”
Get more information

Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse by RABBANI, Farhang, SHEINFELD, Joel, BOSL, George J, FARIVAR-MOHSENI, Hesam, LEON, Antonio, RENTZEPIS, Michael J, REUTER, Victor E, HERR, Harry W, MCCAFFREY, John A, MOTZER, Robert J, BAJORIN, Dean F

“…To determine the incidence, pattern, and predictive factors for relapse in patients with low-volume nodal metastases (stage pN1) at retroperitoneal…”
Get full text

Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors by Motzer, R J, Mazumdar, M, Gulati, S C, Bajorin, D F, Lyn, P, Vlamis, V, Bosl, G J

“…Between 20% and 30% of patients with advanced germ cell tumors (GCTs) fail to have durable complete response to conventional cisplatin-based induction…”
Get more information

Surgery for a post-chemotherapy residual mass in seminoma by Herr, H W, Sheinfeld, J, Puc, H S, Heelan, R, Bajorin, D F, Mencel, P, Bosl, G J, Motzer, R J

“…We attempted to select patients for surgery of post-chemotherapy residual mass in advanced seminoma. A total of 55 patients with advanced seminoma underwent…”
Get more information

Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site by Motzer, R J, Rodriguez, E, Reuter, V E, Bosl, G J, Mazumdar, M, Chaganti, R S

“…A minority of patients with poorly differentiated carcinoma achieve a complete response to cisplatin therapy. Recently, specific chromosomal abnormalities have…”
Get more information

Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis by Brenner, P C, Herr, H W, Morse, M J, Sheinfeld, J, Aprikian, A, Bosl, G J, Motzer, R J, Bajorin, D F, Schantz, S, Fair, W R, Burt, M

“…We report our experience with simultaneous resection of residual masses above and below the diaphragm in patients with metastatic nomseminomatous germ cell…”
Get more information

Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin by Xiao, H, Mazumdar, M, Bajorin, D F, Sarosdy, M, Vlamis, V, Spicer, J, Ferrara, J, Bosl, G J, Motzer, R J

“…To assess the durability of response and overall survival for patients with good-risk metastatic germ cell tumors (GCT) treated with four cycles of etoposide…”
Get more information

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up by Schultz, P K, Herr, H W, Zhang, Z F, Bajorin, D F, Seidman, A, Sarkis, A, Fair, W R, Scherr, D, Bosl, G J, Scher, H I

“…To determine survival in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and to analyze prechemotherapy and postchemotherapy…”
Get more information